Management of skin toxicity related to the use of imatinib mesylate

ISSN： 1369-1643

Source： Sarcoma, Vol.9, Iss.3-4, 2005-09, pp. : 157-160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib Mesylate: A Review of Its Use in Chronic Myeloid Leukemia

By Curran M.P. Croom K.F. Goa K.L.

American Journal of Cancer, Vol. 2, Iss. 6, 2003-01 ,pp. : 439-454

Adis International

Access to resources Recommend Favorite

Keratoacanthomas associated with imatinib mesylate

By Balagula Yevgeniy Busam Klaus J. Carvajal Richard D. Wolchok Jedd D. Myskowski Patricia L.

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 593-595

Informa Healthcare

Access to resources Recommend Favorite

Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor

Current Cancer Therapy Reviews, Vol. 1, Iss. 1, 2005-01 ,pp. : 93-108

Bentham Science Publishers

Access to resources Recommend Favorite

Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors

By Tonyali Onder Coskun Ugur Yildiz Ramazan Karakan Tarkan Demirci Umut Akyurek Nalan Benekli Mustafa Buyukberber Suleyman

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 768-773

Humana Press, Inc

Access to resources Recommend Favorite

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer

By Modi Shanu

Breast Cancer Research and Treatment, Vol. 90, Iss. 2, 2005-03 ,pp. : 157-163

Springer Publishing Company

Access to resources Recommend Favorite